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1. Introduction
The era of rational drug design started with conclusion of Paul Ehrlich that substances, which
are used to dye bacteria for their visualization under the microscope, must interfere with
bacterial cells. If so, some of them may interfere lethally and therefore Ehrlich started system‐
atic search on the action of various dyes (and further other organic compounds) on bacterial
growth. In that manner he had discovered first synthetic antibacterial agent – arsphenamine,
Salvarsan (Figure 1), a cure for syphilis [1]. These studies initiated the concept of chemotherapy
and brought him the Nobel Prize in 1908. Paul Ehrlich studied medicine at the University of
Wrocław (then Breslau) and therefore this chapter is dedicated to him and his achievements.
Gerhard Domagk who, at the Bayer Laboratories of the IG Farben conglomerate in Germany,
studied the effect of new synthetic dyes on streptococci continued his idea [3]. One of the dyes,
namely sulfonamidochrysoidine, namely Prontosil Rubrum (Figure 1) for its red color, appeared
to be promising antibacterial agent in mice [4]. Researchers at the French Pasteur Institute
found, at the end of 1935, that prontosil is metabolized to sulfanilamide, which acts as real
antibiotic. It inhibits multiplication of bacteria by acting as antimetabolite of p-aminobenzoic
acid in the folic acid metabolism cycle. Sulfanilamide is considered as isosteric and isoelec‐
tronic analogue of p-aminobenzoic acid because its three dimensional and electronic structure
resembles closely that of the metabolite (Figure 2).
This discovery started an era of effective and popular technique called structural analogy,
which has been popularly used for designing and development of innovative drugs.
In 1939 Domagk received the Nobel Prize in Medicine for discovery of the first drug effective
against bacterial infections but he was forced by Nazi regime to refuse the prize. He received
it after the war in 1947.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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Figure 1. Structures of Salvarsan (actual oligomeric structure is differing from that proposed by Ehrilch [2]) and Pronto‐
sil Rubrum
Figure 2. Structures of p-aminobenzoic acid and sulfanilamide
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2. Direct similarity as a basic tool of structural analogy
Concept of structural analogy gave an impetus to general search for antimetabolites of
therapeutic utility. The principal approach involves introduction of minor changes to the
chemical structure of chosen metabolite by replacement of its specific functional groups by
related ones, most likely isosteric and isoelectronic. The invention of anticancer drug, metho‐
trexate, is one of the oldest examples of successful implementation of this methodology [5].
Methotrexate is N-methylated aminopterine, a formal antimetabolite of folic acid. In the case
of aminopterine and methotrexate hydroxyl group of pteridynyl fragment of folic acid is
replaced by amino moiety (Figure 3).
Figure 3. Structures of folic acid and its analogues
A good example how minute modifications introduced to the structure of the drug change the
activity of the new molecule is a comparison of the activity of analogues of morphine [6].
Morphine is an opioid analgesic drug and the main psychoactive component of opium. In
order to avoid its addictive action a wide variety of structural analogues of this drug have been
synthesized, with representative ones shown in Figure 4. This example also illustrates that the
application of the theory of structural analogy is quite cumbersome because it requires
synthesis of many new structurally related chemical entities in order to evaluate how small
structural changes introduced to parent molecule affect its biological activity.
Sometimes quite surprising results are obtained as it is illustrated by the activity of phosphinic
acid analogue of γ–aminobutyric acid (GABA). GABA is a chief inhibitory neurotransmitter
in mammalian central nervous system. There are two classes of GABA receptors: GABAA and
GABAB. GABAA receptors are ligand-gated channels, whereas GABAB are G protein-coupled
receptors. In order to understand their physiologic functions a molecular tools able to switch
one of the receptors when not influencing the other one are required. The activating affinity
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of GABA to the two receptors is equal and values 20 nM. Fortunately, its phosphinic acid
analogue is 4,500 times more selective towards GABAB receptor, with affinity of 1 nM [7].
Figure 5. GABA and its phosphinic acid analogue
Theory of structural analogy is most commonly used to modify structures of the known drug
molecules. This process is called drug optimization and is done in order to enhance drug
secondary properties such as: absorption, stability, distribution, metabolism and toxicity. This
is also cumbersome and time-consuming process. However, there are some indications that
help to achieve the goal. A useful example is modification of geldanamycin, an antimelanotic
compound isolated from Streptomyces hygroscopicus. It binds to Heat Shock Protein 90 and alters
its function inducing degradation of proteins that are mutated in tumor cells. Despite its potent
antitumor potential, geldanamycin presents several major drawbacks as a drug candidate,
with hepatotoxicity being the most dangerous. That is why Kosan Biosciences introduced
improved geldanamycins obtained by replacement of methoxyl at the 17 position by allyla‐
mine group (Figure 6) [8]. This modification additionally improved solubility of the drug.
Another example is the modification of the structure of valacyclovir, an antiviral agent
produced by GlaxoSmithKline, active against Herpex simplex and Herpex zoster. It is a prodrug
since the hydrolysis of L-valine releases popular antiviral agent – acyclovir. Replacement of
Figure 4. Structure-activity relationship in morphine analogues
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valine by aminocyclopropanecarboxylic acid (Figure 6) improves the stability of the prodrug
and results in the increase of its oral availability [9].
Figure 6. Improvement of drug action by use of structural analogy approach
In some cases small modification of the drug structure led unexpectedly to change of its mode
of action [10,11]. This might be considered as both shortcoming and advantage of this techni‐
que. For example, modifications of promethazine (Figure 7), which is a first generation of H1
receptor antagonist being used medically as antihistamine antiemetic to prevent motion
sickness, nausea or vomiting and itching associated with allergies, led to chlorpromazine,
which works on a variety of receptors in the central nervous system, producing anticholinergic,
antidopaminergic, antihistaminic and weak antiadrenergic effects. Thus, it is used to treat
psychotic disorders such as schizophrenia and bipolar disorder. Another minute modification
of promethazine structure led to imipramine, which is mainly used for the treatment of major
depression, panic disorder and enuresis (inability to control urination).
A new dimension to the structural analogy approach was brought by development of combi‐
natorial chemistry. It is essentially a collection of techniques, which allow rapid and parallel
synthesis of multiple compounds at the same time and then to select the compound of the
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highest activity. These techniques are now largely automated, what causes that collections of
compounds (libraries) are made easily and might be fast evaluated towards chosen molecular
target. Thus, application of combinatorial chemistry enables to overcome long-lasting and
cumbersome stepwise synthesis of structural analogues of certain drug candidate [12].
In humans, 23 matrix metalloproteinases (MMPs) have been identified. The association of
MMPs with a variety of pathological states has stimulated impressive efforts over the past 20
years to develop synthetic compounds able to block efficiently the uncontrolled activity of
these enzymes [13]. Extremely potent inhibitors of MMPs have been developed, but in most
cases these compounds act as broad spectrum ones [14]. The development of selective
inhibitors for each MMP is a difficult goal to achieve because of the high structural similarity
between the different members of this enzyme family [15]. Synthesis based on a combinatorial
approach and screening of libraries containing pseudopeptides with an isoxazole motif in the
P1’ position (Figure 8) has led to the identification of a highly selective inhibitor of the
macrophage elastase (MMP-12), a potential drug against atheroma plaque rupture [16].
Figure 8. Discovery of selective inhibitor of MMP-12 by combinatorial approach
Another modification of structural analogy approach is to use protein structures found by X-
ray crystallography or NMR as a template to design potential drugs by computer-assisted
Figure 7. Structures of promethazine, chlorpromazine and imipramine
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procedures. Idea of this technique is similar to combinatorial chemistry in that the libraries of
structural analogues of certain drugs are designed. Then the computer “docks” each molecule
from the chosen library into target’s binding site and scores its geometric and electrostatic fit.
There are quite a big number of docking programs available and all of them predict the possible
binding of a ligand by calculating the contribution of certain types of interactions to overall
affinity. Thus, it is possible to analyze in silico drug activity from the first principles of quantum
mechanics and to determine the key interactions crucial for inhibitory activity [17]. Finally,
most promising compounds are being synthesized and their physiologic activity is evaluated.
Tuberculosis is one of the most wide-spread infections with the highest mortality among
diseases caused by a single pathogen [18]. Due to the multi-drug resistance strains of Myco‐
bacterium tuberculosis-disease’s causative agent, novel antituberculosis drugs are rapidly
needed. It releases significant amounts of proteins to the extracellular space, among which
glutamine synthetase is one of the most abundant. Glutamine synthetase is the major enzyme
involved in nitrogen metabolism in plants and bacteria. It catalyzes reaction of glutamate with
ammonium ion, in the presence of ATP, which leads to glutamine [19]. Additionally, in case
of pathogenic mycobacteria it is crucial for biosynthesis of cell wall component, poly-L-
glutamate/glutamine. X-ray structure of bacterial glutamine synthetase complexed with
phosphinothricin [20], a potent inhibitor of this enzyme, was used for computer-aided
structure-based design of the inhibitors (Figure 9), in which the methyl group of phosphino‐
thricin was chosen as the modification site. Thus, the classic structural analogy approach was
used. Among 25 structures predicted by used LUDI program [21] the compounds with amino
and hydroxyl moieties introduced into the phosphinic acid portion of the lead molecule were
found to interact with ammonium binding site in the active cleft of the enzyme and also
appeared to be the effective inhibitors of glutamine synthetase [22].
Figure 9. Inhibitors of glutamine synthetase predicted by computer-aided technique basing on phosphinothricin struc‐
ture
It is worth to mention that not all the structures designed by program had been synthetically
available and that chemical synthesis still is the most challenging step in innovative drug
development as illustrated in Figure 10 summarizing approaches to obtain these two ana‐
logues of phosphinithricin.
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Figure 10. Synthetic routes to analogues of phosphinothricin
3. Modification of structural analogs — How far the structure of drug may
differ from the parent molecule
Methotrexate was developed to inhibit mammalian folate metabolism and thus act as anti‐
cancer drug. Its discovery is considered as one of the milestones in modern chemotherapy [23].
It is used to treat various cancers but also severe psoriasis and rheumatoid arthritis. Interest‐
ingly, first developed to treat malignancies it is now used to treat gynecological problems [24].
As shown in Figure 11, the structure of methotrexate could be divided into some blocks, for
which structural analogues might be designed. In the first step these modifications are minute
ones and mainly relay on the replacement of chosen fragments by isosteric and isoelectric ones
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as represented by such drugs as: Leucovorin, Talotrexin, Tomudex and Alimta [25-27]. Further
modifications lead to the drugs less and less resembling folic acid, as it is well demonstrated
by the structures of antimalarial drugs Trimethoprim and Cycloguanil [28].
Figure 11. Analogues of methotrexate
There is a growing medical need for new antibacterial agents due to increasing number of
multidrug resistant pathogens. Lipid A (endotoxin), the hydrophobic moiety of lipopolysac‐
charide (LPS), is a glucosamine-based saccharolipid that makes up the outer monolayer of the
Structural Analogy — Direct Similarity Versus Topographical Complementarity
http://dx.doi.org/10.5772/59401
249
outer membranes of most gram-negative bacteria [29]. It is the hydrophobic anchor of LPS and
is essential for bacterial survival. There are approximately 106 lipid A residues in Escherichia
coli. Thus, the biosynthesis of LPS (Figure 12) represents an attractive target for the develop‐
ment of novel antibiotics. LpxC catalyzes simple deacetylation of UDP-3-O-(R-3-hydroxymyr‐
istoyl)GlcNAc, the committed step in the biosynthesis of lipid A. This enzymatic reaction has
been a major research focus for industrial groups and academic laboratories in the last two
decades.
Figure 12. Lipid A biosynthetic pathway
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Simple  replacement  of  acetyl  group  of  UDP-3-O-(R-3-hydroxymyristoyl)GlcNAc  by
hydroxamate moiety gave promising inhibitor of LpxC. Further reduction of its structure
by  removal  of  hydroxyl  from hydroxymyristic  acid  (and thus  removal  of  chiral  center)
followed by limiting the length of hydrophobic part of the molecule (Figure 13) afforded
low-molecular inhibitor of  LpxC (TU 519)  shown in Figure 13.  Such modifications were
possible  because lipidic  part  of  the substrate  is  not  bound by the enzyme and is  freely
exposed to the environment (Figure 13).
Figure 13. Stepwise reduction of lipidic part of LpxC inhibitor leading to TU 519 and explanation of the molecular ba‐
sis of this process by X-ray structure of the enzyme bound with substrate
Further modifications of the structure of TU 519 molecule, enforced by analysis of crystal
structures of enzyme-inhibitor complexes afforded nanomolar inhibitors of LpxC, however,
none of them reached phase of clinical studies. Anyway, this approach is a good illustration
that stepwise modifications of chemical structure of substrate afford inhibitors, structure of
which is substantially different than parent one.
Neurotensin is a 13-amino acid peptide found in the central nervous system and the gastro‐
intestinal tract. It has been shown to play the seemingly unrelated functions in the central
nervous system and the periphery and thus is involved in a wide range of physiologic and
pathologic processes throughout the body [29]. By selective targeting or blockade of specific
neurotensin receptors potential drugs for use in the treatment of schizophrenia, alcoholism,
chronic pain, or cancer have been found [30].
Meclinertant (SR-48692) is a drug, which acts as a selective, non-peptide antagonist of neuro‐
tensin receptor 1. It is used in research to explore the interaction between neurotensin and
other neurotransmitters in the brain and is considered as potential anticancer agent [31].
Comparison of the modes of binding of neurotensin and SR-48692 indicates that they are
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governed by the same interactions (Figure 15) and illustrates how far the structure of the drug
differs from the structure of parent compound [32].
Figure 14. Inhibitors of LpxC obtained by stepwise modification of TU 519 structure
Figure 15. Binding of neurotensin and meclinertant to NRT1 receptor is governed by the same interactions. Amino
acids of the receptor interacting with specific portions of effectors are represented by colored balls.
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4. Mapping of structural preferences of binding sites of receptors of
peptidyl hormones and enzyme inhibitors
Throughout the body, peptides are active regulators and information brokers with skill sets
that make them interesting for drug discovery. The most commonly the search on peptide-like
drugs is concentrated at discovery of agonists and antagonists of certain hormones and
neuroregulators. On the other hand, short peptides, their analogues and mimetics are com‐
monly applied as inhibitors of proteinases.
In order to introduce a peptide as a drug their low stability in body fluids and the fast clearance
must be overcame. The simplest solution is replacement of terminal amino acids of lead
compound by their enantiomers. This usually improves peptide hydrolytic stability, since
enzymes do not hydrolyze peptide bond formed by D-amino acids.
Replacement of one or few amino acids of chosen hormone by their analogues is perhaps the
oldest and most exploited technique for designing new drugs. Analogues of gonadotropin
releasing hormone may serve as a good example here. This idea is well illustrated by com‐
parison of the structures of four drugs with the structure with gonadotropin releasing hormone
(GnRH) (Figure 16).
GnRH is the hypothalamic factor that mediates reproductive competence. This peptide
composed of 10 amino acids triggers sexual development and it is essential for normal sexual
physiology of both males and females [33]. In both sexes, its secretion occurs in periodic pulses
usually occurring every 1–2 hours. GnRH secretion from the hypothalamus acts upon its
receptor in the anterior pituitary to regulate the production and release of the gonadotropins
luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH then stimulate
sex steroid hormone synthesis and gametogenesis in the gonads. Therefore, analogues of
GnRH are considered as drugs against sexual disorders [34].
Goserelin (Zoladex) obtained by modifications introduced at C-terminal glycine and serine-4
stops the production of sex hormones (testosterone and estrogen) and is used to treat hormone-
sensitive cancers of the prostate and breast (in pre-/perimenopausal women) [35]. Cetrorelix
(Cetrotide) obtained by modifications of GnRH chain in positions 1, 2, 3, 6 and 10 is a synthetic
decapeptide with gonadotropin-releasing hormone antagonistic activity. It is used in assisted
reproduction techniques to prevent premature LH surge in women undergoing controlled
ovarian stimulation allowing the follicles to mature for planned oocyte collection [36].
Third analogue, Leuprolide (Lupron, Leuprorelin), which differs from parent hormone by
modification of both glycines (positions 6 and 10), is used for the palliative treatment of
advanced prostate cancer. In many cases, Lupron may slow or stop the growth of cancerous
cells and relieve some of the associated symptoms [37]. Finally, Nafarelin (Synarel), which was
obtained by replacement of glycine-6 by bulky aromatic non-proteinous amino acid, is used
to relieve the symptoms of endometriosis, including menstrual cramps or low back pain during
menstruation [38]. Synarel is also indicated for use in controlled ovarian stimulation programs
prior to in vitro fertilization [39].
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Of course, it is not possible to predict how the introduced change will reflect in certain activity.
Therefore, cumbersome trials are needed to find out proper drug amongst thousands of
synthesized analogues. It is worth to note that the replacement of each of ten amino acids in
GnRH by 20 proteineous amino acids gives 1020 combinations. If considering that each natural
amino acid could be replaced by many structurally different analogues (representative
structures of analogues of phenylalanine are shown in Figure 17) not systematic approach but
only luck may help to find interesting new drug. Therefore, application of combinatorial
chemistry seems to be an obvious technique here [40].
The approach basing on substitution of amino acids surrounding active centers of proteinases
is also applied for the design of peptidyl or peptidomimetic inhibitors of proteases. In this case,
however, a new technique emerged, which is basing on screening of the activity of large
libraries of fluorogenic substrates of chosen enzymes. This enables to determine substrate
preferences of certain enzyme and thus to provide a set of data useful for the preparation of
their selective inhibitors [41]. This approach, called enzyme profiling, was successfully used
for differentiation of the binding requirements of the same enzymes isolated from different
sources (orthologs) [42-44], which ensures that the inhibitors designed on the basis of this
profiling would be species specific. The utility of this approach was validated by the prepa‐
ration of potent inhibitors of M1 alanine aminopeptidase from Neisseria meningitides [45], a
gram-negative diplococcus bacterium, which is the main causative agent of meningitis. It is
the inflammation of the membranes lining the brain and spinal cord. This disease is particularly
Figure 16. Comparison of structure of GnRH with its four analogues.
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dangerous as it can result in brain damage and eventually, if not treated promptly or left
untreated, can lead to death. It mostly threatens children during the first year of life [45].
5. Inhibitors mimicking three-dimensional structure of active peptides and
protein epitopes
It is well established that only several exposed amino acids of the hormone are responsible for
physiologic effect. Therefore it is of interest to place their side chains in such a way that they
ensure interaction with the appropriate receptor. Ocreotide (Sandostatin) is a drug elaborated
basing on that concept. Somatostatin is a hormone that inhibits the secretion of several other
hormones, including growth hormone, thyroid stimulating hormone, cholecystokinin and
insulin. It has two active forms produced by alternative cleavage of a single preprotein: one of
14 amino acids, the other of 28 amino acids [46]. Ocreotide is an octapeptide, in which similar
strain as in parent shorter hormone was introduced (Figure 18). It results in a similar exposition
of phenylalanine, tryptophan, lysine and threonine. Additionally D-tryptophan and D-
phenylalanine were applied to ensure higher hydrolytic stability of the drug. Ocreotide mimics
Figure 17. Representative variations of the structure of phenylalanine
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somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone,
glucagon, and insulin than the natural one. It is approved for the treatment of acromegaly,
diarrhea and flushing episodes associated with carcinoid syndrome, and for the treatment of
diarrhea in patients with vasoactive intestinal peptide-secreting tumors [47]. Lanreotide
(Somatuline) is a simple analogue of Ocreotide in which C-terminal threoninol was replaced
by threonine amide (Figure 18) [48]. It is also approved as a drug against acromegaly, a
hormonal disorder that results when the pituitary gland produces excess growth hormone
(GH). It most commonly affects middle-aged adults and can result in serious illness and
premature death.
Figure 18. Somatostatin and its analogues: Ocreotide and Lanreotide
The next generation of analogues started with discovery of Ocreotide structural analogue,
L-363,301 hexapeptide (Figure 19) bearing properly exposed side chains of phenylalanine,
tryptophan, lysine and threonine and displaying high biological activity in inhibiting the
release of growth hormone, insulin, and glucagon [49]. Quite interestingly N-methylation of
tryptophan, lysine and phenylalanine of this peptide resulted in its elevated oral bioavailability
[50]. This finding served as inspiration for the development of somatostatin analogues, in
which the side-chains of four amino acids responsible for physiologic effect are placed on cyclic
scaffolds. The representative examples of compounds obtained by this approach are shown in
Figure 19 and include: a backbone-cyclic somatostatin analogue PTR 3046 [51], a selective
agonist of one out of five receptors (SSTR5 receptor); tetrapeptide composed of four β-amino
acids [52]; N-peptoid analog of the cyclo β-peptide of low micromolar affinity but strong
selectivity towards SSTR5 receptor [53] and somatostatin mimetic, based on the D-glucose
scaffold considered as the landmark on this field [54]. Unfortunately none of these compounds
have found an application in medicine, however, discovery of Pasireotide (Signifor) (Figure
19) is an example of successful implementation of this strategy. Pasireotide is an orphan drug
approved in U.S.A. and Europe for the treatment of Cushing’s disease in patients who fail or
are in ineligible for surgical therapy [55].
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Figure 19. Analogues of somatostatin built-up on cyclic scaffolds
Similar approach was used for design antagonists and agonists of γ-agatoxin IVB. It is one of
the toxins extracted from American funnel web spider Agelenopsis aperta. This 48 amino acid
protein is a very selective antagonist of the P-type calcium channels. Because γ-agatoxin IV
docks to the channel protein via loop composed of eight amino acids, which are located
between the 11 and 18 amino acids, this fragment was chosen to find the minimal sequence,
which possesses the activity of calcium channel modulators. Therefore, constrained cyclic
analogues with three-dimensional arrangement corresponding to the native structure of the
loop were designed (Figure 20). The neurophysiological experiments confirmed the proper
choice of the mimetics and the necessity of the presence of properly directed tryptophan (an
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amino acid fundamental for activity) residue for toxin-channel interactions [56,57]. The
synthesized agonists might be useful for the development of treatment for patients with
calcium like migraine, related to decreased calcium influx.
Figure 20. Structure of γ-agatoxin IVB and two of its simplified analogues.
Human immunodeficiency virus (HIV) entry is a complex and intricate process that facilitates
delivery of the viral genome to the host cell. For entry to occur the outer viral envelope protein
gp120 sequentially engages the host protein CD4. The exact mechanism by which the virus
enters the cell is not known in detail; however, it is known that gp120 plays a critical role here
[58]. Its role is to seek receptors suitable for viral entry and to fix the viral particle to the cell.
Since gp120 is trimeric, trivalent synthetic miniproteins CD4M9 (analogues of scorpio scylla‐
toxin) [59], mimicking DC4 receptor, were designed to target the CD4-binding sites displayed
in the trimeric gp120 complex of HIV-1 (Figure 21). These miniproteins bound via thiol
moieties to symmetrical scaffolds demonstrated significantly enhanced anti-HIV activities
over the monomeric ones [60].
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Figure 21. Triad of miniproteins CDM9 bound to synthetic scaffolds
6. Topographical complementarity as a mean for inhibitor design
Human hormone effectors such as: meclinertant (neurotensin receptor, Figure 13), ezlopitant
(neurokinin receptor) [61], CP-154,526 (corticotropin-releasing hormone receptor) [62],
SM-130,686 (growth hormone secretatogue) [63], asperlicin (cholecysatokinin receptor) [64] or
galantanamine (nicotinic receptor) [65], have been discovered either by serendipity or were
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isolated from natural sources. Their structures are significantly different from natural hor‐
mones (Figure 22) and therefore it is very difficult to design drugs basing on binding modes
of these hormones with their receptors.
Figure 22. Structures of chosen effectors of hormone receptors
Although today it is not possible to design rationally new drugs of this kind, some hope is
brought with development computer-aided methods. The search for compounds with similar
activity to the reference ligand but with different molecular frameworks have been named
“scaffold hopping” or “leapfrogging” [66]. It basically relays on three-dimensional similarity
searching. However, an adequate description of chemical structures in 3D conformational
space is difficult due to the high-dimensionality of the problem and this methodology might
be considered as being in its infancy so far [67].
Other solution is the application of peptidomimetics. They derive from natural peptides and
proteins and are obtained by structural modifications using unnatural amino acids, replace‐
ment of peptide bond by appropriate surrogates or introduction of conformational restrains.
Peptidomimetics represent an important field in chemistry as they circumvent the limitations
of traditional peptides used in therapy. Self-structural organizations such as turns, helices,
sheets and loops can be accessed by this way [68,69].
Antimicrobial peptides are an important component of the natural defense of most living
organisms against invading pathogens. These are relatively small, cationic and amphipathic
peptides of variable length, sequence and structure. Magainins are a class of antibacterial
peptides isolated from the surface of skin of African clawed frog Xenopus laevis [70]. They
disrupt only the bacterial membranes possibly via toroidal-type pore formation and have
minimal interaction with the mammalian cell membranes. It is believed that the structure of
the magainins-in particular a long, repeating helix-is important to their bactericidal activities.
Although strongly active in vitro, are effective in animal models of infection only at very high
doses, often close to the toxic ones, reflecting an unacceptable margin of safety.
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A series of peptides composed of only two strained β-amino acids (Figure 23) were designed
in order to posses helical structure and display required optimal amount of cationic residues
versus hydrophobic ones (in ratio 4:6) at the helical surface. They appeared to be strongly
antibacterial and act in a similar manner as magainins. Moreover, they appear to lack hemolytic
activity and are resistant to action of proteinases, which are the major drawbacks of the parent
compounds [71,72]. Similar, although less spectacular, effect was obtained with oligo-β-
peptides obtained using analogues of natural amino acids [73].
Figure 23. Amphiphilic structure of magainin and its topographical analog
N-Substituted poly(glycines), called peptidoids, are another subclass of peptidomimetics. Such
oligomers, mimicking magainins, with facially amphipathic, cationic, water-soluble sequences
have also been shown to form very stable helices and exhibit antibacterial properties [74].
The findings that nonhelical analogues are nonetheless active against bacterial pathogens
encouraged to further simplify search for new magainin mimetics and pursue alternative
design concepts. Application of poly(arylamides) appears to be successful. The structure of
these molecules is shown in (Figure 24) and indicates that their backbone design has nothing
in common with parent compounds. They have a rigid backbone made from amide-linked
aromatic repeat units, which are further stabilized by hydrogen bonding between a thioester
and the hydrogen on an amide group. This locks the pendant hydrophobic t-butyl groups and
the hydrophilic ammoniums group on opposite sides of the molecule as it is in the case of
magainins (Figure 24). It was shown that such foldamers were active against a number of gram-
positive and gram-negative bacterial strains [75,76]. This finding stimulates an intensive
research on polymeric mimicks of magainins and shows that topographical similarity has not
to be very strict [77].
The described above topographical approach have been also used to produce mimetics of
enzymes, hormones [77] and lung surfactants [78,79]. Lung surfactants are a complex mixture
over 50 lipid species lining the alveolar air-liquid interface. They are indispensable for proper
functioning of the lungs and their absence or dysfunction leads to severe respiratory disease.
The application of exogenous lung surfactants to treat neonatal distress syndrome dramatically
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improved premature infant survival and respiratory morbidity [80]. The possible application
of their stable analogues is considered as a next step in curing this disease.
7. Conclusions
Analogy plays an important role in scientific research. Analogue-based approach of drug
design is one of the oldest methodologies of medicinal chemistry and still is intensively
exploited one. It started from production of antimetabolites by simple replacement of small
functional groups in physiologically important molecules by isosteric and isoelectronic
substituents. The development of biochemistry and pharmacology resulted in search for
substances mimicking three-dimensional architecture of biologically active substances rather
than seeking for simple analogues. Enforced by new techniques, such as combinatorial
chemistry and computer-aided drug design, structural analogy is a reach source of new
substances of potential medical importance.
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